BAX and breast cancer: To outline the influence of ruthenium-fluvastatin therapy on mammary cancer in rats, immunohistochemical staining approaches have been used to determine the existence of cellular biomarkers such as Bax, Bcl2, p53, and MMP9 (Figure 13) (Table 7).